Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855023 | 0.91 | GNRHR (0.39) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4864354 | 0.90 | GNRHR (0.42) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL6644161 | 0.87 | CYP2C9 (0.38) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4863834 | 0.84 | S1PR4 (0.47) | CYP2C9GAAMEN1KMT2ANPSR1 | |
| SCHEMBL4863372 | 0.83 | S1PR4 (0.40) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4862543 | 0.83 | FPR1 (0.44) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4855584 | 0.83 | GNRHR (0.45) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4852317 | 0.83 | GNRHR (0.42) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL4857405 | 0.82 | GNRHR (0.47) | ADORA3DRD1HTR2AOPRM1GNRHR | |
| SCHEMBL14086966 | 0.81 | GNRHR (0.35) | ADORA3DRD1HTR2AOPRM1GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | claimed |
| EP-1644385-B1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-08-29 | — | — | EP | claimed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | claimed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1644385-B1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-08-29 | — | — | EP | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110708-A1 | Silicon compounds and their use | SOST, SMAD3, SMAD2 | ADORA3 4741/4885DRD1 3910/4885HTR2A 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.